{"product_id":"tpst-pestle-analysis","title":"(TPST) Tempest Therapeutics, Inc. PESTLE Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Tempest Therapeutics, Inc. PESTLE Analysis helps you understand the political, economic, social, technological, legal, and environmental forces shaping the company’s risks and opportunities; this page includes a real preview of the report so you can judge style and depth before buying—purchase the full version to receive the complete, ready-to-use company-specific analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePolitical factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA IND oversight for 2 Phase 1 oncology assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTempest Therapeutics relies on US FDA IND oversight for 2 first-in-human oncology programs, TPST-1495 and TPST-1120. These solid-tumor Phase 1 trials need ongoing safety reports, dose-escalation checks, and protocol compliance, so any FDA delay can push readouts and weaken investor confidence. With 2 assets at this stage, regulatory pace is a direct value driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUS cancer-policy priority\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUS cancer policy still puts oncology at the center of federal health spending, with the Cancer Moonshot targeting a 50% cut in the cancer death rate over 25 years. That keeps NCI funding, NIH grants, and FDA review focus tilted toward serious, unmet-need cancers. Tempest Therapeutics can benefit because this policy mix favors innovative oncology drugs and faster clinical development paths.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCalifornia life-science policy base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTempest Therapeutics, Inc. is based in South San Francisco, inside California’s biotech core, where dense lab space, CROs, and trial sites cut hiring and development friction. The tradeoff is cost: California’s corporate income tax is 8.84%, and the state minimum wage is $16.50 an hour in 2025, which can push up R and D and operating spend. \u003c\/p\u003e\n\u003cp\u003eThat same cluster still helps Tempest recruit scarce scientific talent fast and tap nearby research networks. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGeopolitical supply-chain exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTempest Therapeutics, Inc. depends on global suppliers for reagents, API, and lab services, so any trade frictions, customs delays, or import limits can slow trial work and raise costs. For a clinical-stage biotech with little inventory buffer, even a short disruption can push study timelines and burn more cash. This risk is highest when critical inputs come from a small set of overseas vendors.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eGlobal sourcing raises delay risk.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eImport rules can lift costs fast.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eLow inventory makes Tempest Therapeutics, Inc. exposed.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDrug-pricing politics in oncology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUS drug-pricing politics are intense in oncology: Medicare, which covers about 66 million people, started negotiating prices for 10 drugs in 2024, with the first lower prices taking effect in 2026, and 15 more drugs were added for 2027. For Tempest Therapeutics, Inc., payer acceptance and scrutiny of cancer pricing will shape any future launch price and access. Early clinical differentiation will matter most if assets reach late stage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMedicare price pressure is already real\u003c\/li\u003e\n\u003cli\u003eOncology faces the harshest scrutiny\u003c\/li\u003e\n\u003cli\u003eDifferentiation supports pricing power\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTempest Faces Rising FDA, Pricing, and California Cost Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical risk for Tempest Therapeutics, Inc. is highest in FDA review pace, oncology funding, and US drug pricing. Medicare’s 2024 price negotiation covers 10 drugs, with lower prices starting in 2026, and 15 more drugs added for 2027. California also raises cost pressure with an 8.84% corporate tax and a $16.50 minimum wage in 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003cth\u003eTempest Therapeutics, Inc. impact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA oversight\u003c\/td\u003e\n\u003ctd\u003e2 IND-stage oncology programs\u003c\/td\u003e\n\u003ctd\u003eTrial timing risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare pricing\u003c\/td\u003e\n\u003ctd\u003e10 drugs in 2024; 15 more for 2027\u003c\/td\u003e\n\u003ctd\u003eFuture launch pricing pressure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCalifornia costs\u003c\/td\u003e\n\u003ctd\u003e8.84% tax; $16.50 wage in 2025\u003c\/td\u003e\n\u003ctd\u003eHigher R and D spend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAssesses how six macro factors shape Tempest Therapeutics, Inc.’s risks and opportunities across Political, Economic, Social, Technological, Environmental, and Legal dimensions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise Tempest Therapeutics PESTLE snapshot that quickly highlights external risks and opportunities for easier planning and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable sources list linking Tempest Therapeutics’ market, clinical, and financial claims to primary industry reports, datasets, and peer-reviewed benchmarks for fast due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEconomic factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical-stage cash burn\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTempest Therapeutics, Inc. has no marketed product, so its funding depends on outside capital and periodic equity raises. Phase 1 oncology trials are costly for a company of this size, and that makes cash burn a core economic risk. The main pressure points are runway, financing timing, and dilution if new shares must be issued before data readouts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh cost of solid tumor trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTempest Therapeutics, Inc. faces high solid-tumor trial costs because these studies need specialized sites, biomarker testing, and close patient monitoring. Industry estimates put Phase 1 site start-up at about $50,000-$100,000 per site, while biomarker work can add $200-$1,000 per patient. Costs usually jump again in expansion cohorts, and any delay can lift burn and extend timelines fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotech funding volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSmall-cap biotech funding stays cyclical, and Tempest Therapeutics is exposed to that swing. One weak trial readout can cut equity access fast, so the company’s valuation can move sharply with market sentiment. In 2025, investors still favored proven late-stage data over early-risk names, keeping funding terms tight.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInterest-rate environment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHigher rates keep Tempest Therapeutics, Inc.’s cost of capital high, and the Fed’s 4.25%-4.50% target range in 2025 kept financing conditions tight for loss-making biotech. That matters because unprofitable drug developers often need repeated equity raises, and each round gets harder when investors demand lower valuations. For Tempest Therapeutics, Inc., the result is a higher hurdle for follow-on funding and a weaker market for long-duration clinical risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh rates raise dilution risk.\u003c\/li\u003e\n\u003cli\u003eBiotech appetite stays selective.\u003c\/li\u003e\n\u003cli\u003eFollow-on financing gets tougher.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartnering and M and A leverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOncology assets are often priced off licensing or M\u0026amp;A, and first-in-human data can swing valuation fast. For Tempest Therapeutics, Inc., clean safety and early efficacy readouts are key to attracting non-dilutive capital, because deal terms usually tighten if the package looks weak. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEarly data drives partner interest.\u003c\/li\u003e\n\u003cli\u003eStrong Phase 1 signals raise price.\u003c\/li\u003e\n\u003cli\u003eWeak readouts cut leverage fast.\u003c\/li\u003e\n\u003cli\u003eDeal terms reflect clinical de-risking.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIn 2025, biopharma dealmaking stayed concentrated in oncology, where buyers pay for proof-of-concept more than platform promises. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTempest’s 2025 survival hinges on costly financing and trial timing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTempest Therapeutics, Inc. remains a cash-burning, pre-revenue biotech, so 2025 financing terms are the key economic driver. Higher rates kept capital expensive, with the Fed at 4.25%-4.50%, and oncology deal flow stayed selective. Any trial delay can lift burn and force a dilutive raise.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed rate\u003c\/td\u003e\n\u003ctd\u003e4.25%-4.50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 1 site start-up\u003c\/td\u003e\n\u003ctd\u003e$50k-$100k\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiomarker testing\u003c\/td\u003e\n\u003ctd\u003e$200-$1,000\/patient\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eTempest Therapeutics, Inc. PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Tempest Therapeutics PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use.\u003c\/p\u003e\n\u003cp\u003eNo placeholders or teasers—what you see in this snapshot is the final document you’ll download immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSociological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising cancer burden\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCancer remains a major public-health burden, with about 20 million new cases and 9.7 million deaths worldwide in 2022. Most cancers are solid tumors, so demand for new therapies stays high across large patient pools. For Tempest Therapeutics, Inc., that means it operates in a market with deep unmet need and ongoing clinical demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient preference for targeted therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatients and oncologists increasingly back therapies with a clear biological story, and Tempest Therapeutics, Inc.'s TPST-1495 and TPST-1120 fit that pull through receptor and pathway targeting. In a market where 1 strong mechanism can lift trial interest and adoption, Tempest Therapeutics, Inc. can use this science-led positioning to stand out in Phase 1\/2 development and build trust.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial participation barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClinical trial enrollment in oncology is still hard: only about 3% to 5% of adult cancer patients join trials, and access often depends on distance to major centers, referrals, and health status. For Tempest Therapeutics, Inc., that means small patient pools and slower screening can stretch timelines and lift trial costs. In a field where every month delays readouts, enrollment risk can hit cash burn fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDemand for better tolerability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSolid-tumor care often means 2+ prior therapy lines, so patients and oncologists favor drugs that add efficacy without harsh toxicity. With about 2,041,910 new U.S. cancer cases expected in 2025, Tempest Therapeutics, Inc. must position early assets around clear benefit-risk and easy combination use.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2+ prior lines raise safety demands\u003c\/li\u003e\n\u003cli\u003e2025 U.S. cases: 2,041,910\u003c\/li\u003e\n\u003cli\u003eBetter tolerability helps combo uptake\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEquity in trial access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDiversity gaps in oncology trials still limit how well safety and efficacy data reflect real patients; Black people are 13.6% of the U.S. population, so Tempest Therapeutics, Inc. needs broader reach to avoid skewed data.\u003c\/p\u003e\n\u003cp\u003eBroader enrollment makes efficacy and safety results more reliable across age, race, and geography. Tempest Therapeutics, Inc. should pick sites near diverse patient pools and use local outreach to lift access.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUse diverse sites\u003c\/li\u003e\n\u003cli\u003eExpand local outreach\u003c\/li\u003e\n\u003cli\u003eImprove data relevance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Cancer Demand Raises Tempest’s Trial Access and Diversity Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOncology demand stays high, with 2,041,910 U.S. cancer cases expected in 2025 and only 3% to 5% of adults joining trials. For Tempest Therapeutics, Inc., that makes access, referral reach, and site location key social risks. Patients and oncologists also favor tolerable, clear-benefit drugs, and diverse enrollment matters because Black people are 13.6% of the U.S. population.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 U.S. cancer cases\u003c\/td\u003e\n\u003ctd\u003e2,041,910\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdult trial enrollment\u003c\/td\u003e\n\u003ctd\u003e3%-5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBlack share of U.S. population\u003c\/td\u003e\n\u003ctd\u003e13.6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eTechnological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDual EP2 and EP4 inhibition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTempest Therapeutics, Inc.'s TPST-1495 is built to block both EP2 and EP4, two prostaglandin E2 receptors, in one molecule. That dual hit is meant to lower tumor-driven immune suppression and support T-cell activity, which fits a pathway-based cancer immunology strategy. The design is notable because EP4 and EP2 signaling are both linked to a pro-tumor, immune-evasive microenvironment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePPAR alpha blockade\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTPST-1120 is Tempest Therapeutics, Inc.’s lead small-molecule blocker of peroxisome proliferator-activated receptor alpha (PPARα), a 1-target approach designed to shift tumor metabolism and immune signaling. In oncology, this differentiated mechanism aims to hit both cancer biology and the immune response. That matters because PPARα blockade is a non-checkpoint strategy in a field still dominated by fewer than 10 major immune-drug classes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTREX-1 biology platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTempest Therapeutics, Inc. is also exploring TREX-1, a cellular enzyme that helps control innate immune signaling in cancer, which adds a third discovery lane beyond its 2 clinical candidates. That platform-style approach can widen its target pool and improve optionality if one program stalls. The key point: TREX-1 can support broader pipeline growth without adding a new company.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBiomarker-driven development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBiomarker-driven development is key for Tempest Therapeutics, Inc. because modern oncology trials work best when they find the right patient subgroup early. In biomarker-selected cancer studies, response rates can be far higher than in unselected groups, so early translational signals can lift trial success odds and guide later-stage design. That also helps Tempest avoid spending scarce cash on broad, low-signal studies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFind responders early\u003c\/li\u003e\n\u003cli\u003eRefine later-stage trial design\u003c\/li\u003e\n\u003cli\u003eReduce wasted development spend\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSmall-molecule manufacturing advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTempest Therapeutics, Inc.'s small-molecule focus can be a real manufacturing edge because these drugs are usually easier to scale than biologics, which often need complex cold-chain handling and specialized facilities. Oral dosing can also cut logistics friction and improve patient use, which matters if the science works and Tempest moves toward commercialization. That lower production burden can help protect margins and speed launch planning.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSmall molecules scale more easily.\u003c\/li\u003e\n\u003cli\u003eOral dosing can simplify delivery.\u003c\/li\u003e\n\u003cli\u003eLower complexity can support margins.\u003c\/li\u003e\n\u003cli\u003eCommercial upside depends on efficacy.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTempest’s Small-Molecule Cancer Bet Targets Tumor-Immune Pathways\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTempest Therapeutics, Inc. uses small-molecule oncology tech to block EP2\/EP4, PPARα, and TREX-1, so it is betting on tumor-immune and metabolism pathways rather than checkpoint drugs alone. Biomarker-led trial design can lift signal in small studies and cut wasted spend. Oral small molecules also tend to be easier to scale than biologics.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eTech factor\u003c\/th\u003e\n\u003cth\u003eImplication\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTPST-1495\u003c\/td\u003e\n\u003ctd\u003eDual EP2\/EP4 block\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTPST-1120\u003c\/td\u003e\n\u003ctd\u003ePPARα inhibition\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTREX-1\u003c\/td\u003e\n\u003ctd\u003ePipeline expansion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eLegal factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA clinical trial compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTempest Therapeutics must keep every clinical program aligned with FDA IND, GCP, and safety-reporting rules, especially in Phase 1 dose-escalation studies where adverse events are watched in real time. In 2025, FDA issued multiple clinical holds across early oncology programs when safety data or protocols were weak, showing how fast noncompliance can delay development or stop a trial.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatent protection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatent protection is a key legal risk for Tempest Therapeutics, Inc. because it has just 2 early-stage assets, so every year of exclusivity matters. Tempest needs broad patents on chemical matter, methods of use, and formulations to block fast-follow rivals and support future licensing talks. If its IP is weak, partner value and deal leverage can drop fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHIPAA and trial-data privacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOncology trials collect highly sensitive health data, so Tempest Therapeutics must enforce HIPAA controls, vendor checks, and tight data-sharing rules. HHS Office for Civil Rights has already issued HIPAA penalties above $2 million in recent cases, showing the cost of weak privacy controls. A breach can trigger fines, trial delays, and lasting reputational damage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePublic-company disclosure duties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTempest Therapeutics, Inc., as a public biotech, must keep SEC disclosures current, especially on trial data, cash use, and financing. For development-stage firms, even one setback or capital raise can trigger a Form 8-K or amended risk disclosure, and that duty is stricter because data can move fast and shares can swing hard. In 2025, this legal load matters more when the pipeline is still the main value driver.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAccurate SEC reporting is mandatory\u003c\/li\u003e\n\u003cli\u003eClinical news can trigger filings\u003c\/li\u003e\n\u003cli\u003eFinancing updates need fast disclosure\u003c\/li\u003e\n\u003cli\u003eVolatile data raises legal risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eProduct-liability exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTempest Therapeutics, Inc. faces product-liability exposure even in early trials, because serious adverse events can trigger claims, protocol pauses, or regulatory review. With no approved product on sale yet, the main risk sits in clinical testing, where trial insurance, indemnities, and clear informed-consent forms help limit losses.\u003c\/p\u003e\n\u003cp\u003eIf either candidate reaches market, liability risk would jump fast, since post-market claims can be much larger and harder to cap. FDA consent rules under 21 CFR 50 make disclosure of known risks a key legal shield.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTrial-stage risk still matters.\u003c\/li\u003e\n\u003cli\u003eInsurance and indemnities are essential.\u003c\/li\u003e\n\u003cli\u003eCommercial liability would rise sharply.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTempest Faces High Legal and IP Risk Across Trials, Privacy, and Filings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTempest Therapeutics, Inc. faces high legal risk from FDA trial rules, HIPAA privacy duties, and SEC disclosure demands, because one safety or data lapse can delay programs, trigger fines, or force new filings. Patent strength is also critical, since its value depends on protecting a small, early-stage pipeline.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLegal factor\u003c\/th\u003e\n\u003cth\u003eTempest impact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA\/IND\u003c\/td\u003e\n\u003ctd\u003eHold risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHIPAA\u003c\/td\u003e\n\u003ctd\u003ePrivacy fines\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSEC\u003c\/td\u003e\n\u003ctd\u003eFast filings\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP\u003c\/td\u003e\n\u003ctd\u003eExclusivity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEnvironmental factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLaboratory waste management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTempest Therapeutics' oncology R\u0026amp;D can create solvent, sharps, and biohazard waste, so disposal controls must be tight. EPA hazardous-waste rules and OSHA bloodborne-pathogen standards raise handling costs, but they also cut injury and compliance risk. For a small biotech with no product revenue yet, even modest waste fees can bite cash burn and lab efficiency.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnergy use in research operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiotech labs can use 3 to 5 times more energy than typical offices, with -80°C freezers often drawing about 20 to 25 kWh a day. In California, high power prices make facility efficiency a direct cost issue for Tempest Therapeutics, Inc., especially for ventilation and instrumentation. Better energy management can cut expenses and lower Scope 2 emissions in ESG reporting.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClimate-related supply-chain risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClimate-related supply-chain risk can hit Tempest Therapeutics, Inc. hard because storms, heat, and floods can delay shipping, disrupt trial sites, and spoil temperature-sensitive samples. The World Meteorological Organization said 2024 was the warmest year on record, and severe weather is now a recurring logistics threat. For a geographically spread clinical program, even short transport delays can create missed visits, sample loss, and higher trial execution costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCalifornia environmental rules\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTempest Therapeutics, Inc. faces California’s tighter environmental regime, where wet-lab biotech sites must manage chemical storage, waste, air permits, and worker safety under Cal\/OSHA and local rules. California also generated 4.5 million tons of hazardous waste in 2024, so compliance for labs can add real cost and time. For a small biotech, even minor permit delays can slow research schedules.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStrict state rules raise compliance overhead.\u003c\/li\u003e\n\u003cli\u003eHazardous waste handling is a key cost.\u003c\/li\u003e\n\u003cli\u003eWet-lab operations face the biggest burden.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eESG expectations from investors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInstitutional investors now expect clear environmental disclosure, even from small biotechs like Tempest Therapeutics, Inc.; in 2025, global sustainable fund assets were still about $3.2 trillion, showing ESG remains a live capital-market screen. Strong vendor controls, waste and energy policies, and simple reporting can reduce reputational risk and improve access to financing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInvestors want visible ESG data\u003c\/li\u003e\n\u003cli\u003eSmall biotechs are still judged\u003c\/li\u003e\n\u003cli\u003eGood ESG can help funding access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTempest Faces Rising Climate, Energy, and ESG Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTempest Therapeutics, Inc. faces higher lab-waste, energy, and climate-disruption costs as a California wet-lab biotech. EPA\/OSHA and state rules raise handling burden, while 2024 was the warmest year on record, lifting trial and logistics risk. Investor ESG screens still matter, with global sustainable fund assets near $3.2 trillion in 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClimate\u003c\/td\u003e\n\u003ctd\u003e2024 warmest year\u003c\/td\u003e\n\u003ctd\u003eTrial delays\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnergy\u003c\/td\u003e\n\u003ctd\u003e-80C freezer 20-25 kWh\/day\u003c\/td\u003e\n\u003ctd\u003eHigher burn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eESG capital\u003c\/td\u003e\n\u003ctd\u003e$3.2T\u003c\/td\u003e\n\u003ctd\u003eFunding screen\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235129303305,"sku":"tpst-pestle-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/tpst-pestle-analysis.webp?v=1785733946","url":"https:\/\/dcfanalyst.com\/products\/tpst-pestle-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}